REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
REGENXBIO (Nasdaq: RGNX) will present at the 44th Annual J.P. Morgan Healthcare Conference.
Date & time: Wednesday, January 14, 2026 at 10:30 a.m. PT. Location: Westin St. Francis, San Francisco, CA.
A live webcast will be available in the Investors section of the company's website and an archived replay will be posted for approximately 30 days after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction 36 Alerts
On the day this news was published, RGNX gained 2.58%, reflecting a moderate positive market reaction. Argus tracked a peak move of +8.3% during that session. Our momentum scanner triggered 36 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $19M to the company's valuation, bringing the market cap to $769M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Biotech peers showed mixed moves: ARCT -8.04%, ATYR -3.14%, BCYC -5.18% while REPL +0.62% and KOD +1.70%, pointing to stock-specific factors for RGNX’s -6.66% move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 25 | Investor conference | Positive | +10.0% | Announcement of participation in Piper Sandler healthcare conference with webcast access. |
| Nov 06 | Earnings update | Positive | -3.8% | Q3 2025 financials and timelines for RGX-202, RGX-121 and wet AMD programs. |
| Oct 30 | Clinical milestone | Positive | -0.2% | Completion of pivotal AFFINITY DUCHENNE enrollment and start of commercial production. |
| Oct 29 | Earnings call notice | Neutral | -2.4% | Scheduling of Nov 6 call to discuss Q3 2025 financial results and operations. |
| Oct 15 | Investor conferences | Positive | +9.3% | Multiple announced conference appearances with webcast access for investors. |
Investor conference announcements have previously coincided with strong positive moves, while earnings and clinical milestones have sometimes seen muted or negative reactions.
Over the last few months, REGENXBIO highlighted pivotal progress in its Duchenne gene therapy program and maintained an active conference schedule. On Oct 30, 2025, it reported completion of pivotal enrollment for RGX-202 and initial commercial supply preparation. Multiple investor conference participations in Oct–Nov 2025 saw notable positive price reactions. Earnings on Nov 6, 2025 detailed cash of $302.0M and expectations to fund operations into early 2027. Today’s J.P. Morgan conference appearance continues this pattern of sustained investor outreach.
Regulatory & Risk Context
On Nov 26, 2025, REGENXBIO filed an S-3 shelf registration allowing up to $300,000,000 of securities to be offered over time for general corporate purposes, including clinical trial funding, capital expenditures, working capital and potential acquisitions.
Market Pulse Summary
This announcement details REGENXBIO’s planned presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, continuing a pattern of active investor engagement seen in prior conferences. Recent history featured pivotal trial enrollment completion and Q3 2025 results outlining cash of $302.0M and funding expectations into early 2027. The existing $300,000,000 S-3 shelf registration provides capital-raising flexibility, so monitoring future financing actions alongside clinical and regulatory milestones remains important.
AI-generated analysis. Not financial advice.
Presentation Details
Date and Time: Wednesday, January 14, 2026 at 10:30 a.m. PT
Location: Westin St. Francis, San Francisco, CA
A live webcast of the presentation can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302645444.html
SOURCE REGENXBIO Inc.
FAQ
When will REGENXBIO (RGNX) present at the J.P. Morgan Healthcare Conference?
Where is REGENXBIO (RGNX) presenting at the January 2026 J.P. Morgan conference?
How can investors watch the REGENXBIO (RGNX) presentation online?
Will a replay of the REGENXBIO (RGNX) webcast be available after the J.P. Morgan presentation?
What time is 10:30 a.m. PT on January 14, 2026 in Eastern Time for REGENXBIO (RGNX) viewers?
